PMID- 27270337
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Jun 8
TI  - Caffeine administration prevents retinal neuroinflammation and loss of retinal 
      ganglion cells in an animal model of glaucoma.
PG  - 27532
LID - 10.1038/srep27532 [doi]
LID - 27532
AB  - Glaucoma is the second leading cause of blindness worldwide, being characterized 
      by progressive optic nerve damage and loss of retinal ganglion cells (RGCs), 
      accompanied by increased inflammatory response involving retinal microglial 
      cells. The etiology of glaucoma is still unknown, and despite elevated 
      intraocular pressure (IOP) being a major risk factor, the exact mechanisms 
      responsible for RGC degeneration remain unknown. Caffeine, which is an antagonist 
      of adenosine receptors, is the most widely consumed psychoactive drug in the 
      world. Several evidences suggest that caffeine can attenuate the 
      neuroinflammatory responses and afford protection upon central nervous system 
      (CNS) injury. We took advantage of a well characterized animal model of glaucoma 
      to investigate whether caffeine administration controls neuroinflammation and 
      elicits neuroprotection. Caffeine or water were administered ad libitum and 
      ocular hypertension (OHT) was induced by laser photocoagulation of the limbal 
      veins in Sprague Dawley rats. Herein, we show that caffeine is able to partially 
      decrease the IOP in ocular hypertensive animals. More importantly, we found that 
      drinking caffeine prevented retinal microglia-mediated neuroinflammatory response 
      and attenuated the loss of RGCs in animals with ocular hypertension (OHT). This 
      study opens the possibility that caffeine or adenosine receptor antagonists might 
      be a therapeutic option to manage RGC loss in glaucoma.
FAU - Madeira, Maria H
AU  - Madeira MH
AD  - Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, 
      University of Coimbra, 3000-548 Coimbra, Portugal.
AD  - CNC.IBILI, University of Coimbra, 3004-504 Coimbra, Portugal.
FAU - Ortin-Martinez, Arturo
AU  - Ortin-Martinez A
AD  - Departamento de Oftalmologia, Facultad de Medicina, Universidad de Murcia 
      &Instituto Murciano de Investigacion Biosanitaria Hospital Virgen de la Arrixaca 
      (IMIB-Arrixaca), 30100 Murcia, Spain.
FAU - Nadal-Nicolas, Francisco
AU  - Nadal-Nicolas F
AD  - Departamento de Oftalmologia, Facultad de Medicina, Universidad de Murcia 
      &Instituto Murciano de Investigacion Biosanitaria Hospital Virgen de la Arrixaca 
      (IMIB-Arrixaca), 30100 Murcia, Spain.
FAU - Ambrosio, Antonio F
AU  - Ambrosio AF
AD  - Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, 
      University of Coimbra, 3000-548 Coimbra, Portugal.
AD  - CNC.IBILI, University of Coimbra, 3004-504 Coimbra, Portugal.
AD  - Association for Innovation and Biomedical Research on Light and Image (AIBILI), 
      3000-548 Coimbra, Portugal.
FAU - Vidal-Sanz, Manuel
AU  - Vidal-Sanz M
AD  - Departamento de Oftalmologia, Facultad de Medicina, Universidad de Murcia 
      &Instituto Murciano de Investigacion Biosanitaria Hospital Virgen de la Arrixaca 
      (IMIB-Arrixaca), 30100 Murcia, Spain.
FAU - Agudo-Barriuso, Marta
AU  - Agudo-Barriuso M
AD  - Departamento de Oftalmologia, Facultad de Medicina, Universidad de Murcia 
      &Instituto Murciano de Investigacion Biosanitaria Hospital Virgen de la Arrixaca 
      (IMIB-Arrixaca), 30100 Murcia, Spain.
FAU - Santiago, Ana Raquel
AU  - Santiago AR
AD  - Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, 
      University of Coimbra, 3000-548 Coimbra, Portugal.
AD  - CNC.IBILI, University of Coimbra, 3004-504 Coimbra, Portugal.
AD  - Association for Innovation and Biomedical Research on Light and Image (AIBILI), 
      3000-548 Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160608
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 3G6A5W338E (Caffeine)
SB  - IM
MH  - Animals
MH  - Caffeine/*administration & dosage
MH  - Central Nervous System/drug effects/injuries
MH  - Disease Models, Animal
MH  - Glaucoma/complications/*drug therapy/physiopathology
MH  - Humans
MH  - Inflammation/complications/*drug therapy/physiopathology
MH  - Intraocular Pressure/drug effects
MH  - Nerve Degeneration/complications/*drug therapy/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Retina/drug effects/physiopathology
MH  - Retinal Ganglion Cells/drug effects/pathology
PMC - PMC4897621
EDAT- 2016/06/09 06:00
MHDA- 2018/04/24 06:00
PMCR- 2016/06/08
CRDT- 2016/06/09 06:00
PHST- 2016/01/22 00:00 [received]
PHST- 2016/05/10 00:00 [accepted]
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2016/06/08 00:00 [pmc-release]
AID - srep27532 [pii]
AID - 10.1038/srep27532 [doi]
PST - epublish
SO  - Sci Rep. 2016 Jun 8;6:27532. doi: 10.1038/srep27532.